// App-Quantinova.ai

839 : Significant Improvement Of Outcome In Adolescents and Young adults (AYAs) Aged 15-35 Years With Acute Lymphoblastic Leukemia (ALL) With a Pediatric Derived Adult ALL Protocol; Results Of 1529 AYAs In 2 Consecutive Trials Of The German Multicenter Study Group For Adult ALL (GMALL)

Researchers

Presenter

  • Nicola Gokbuget

Principal Investigators

  • Kalina Brandt

  • Stefan Schwartz

  • Hubert Serve

  • Michael Starck

  • Matthias Stelljes

  • Reingard Stuhlmann

  • Andreas Viardot

  • Ralph M. Waesch

  • Knut Wendelin

  • Dietrich Beelen

  • Renate Arnold

  • Monika Bruggemann

  • Dieter Hoelzer

  • Thomas Burmeister

  • Helmut Diedrich

  • Christoph Faul

  • Andreas Huttmann

  • Mustafa Kondakci

  • Doris M Kraemer

  • Oliver G. Ottmann

Medical Centers

  • Department of Hematology/Oncology, Hospital Oldenburg, Oldenburg, Germany

  • Hematology and Oncology, Charite Campus Benjamin Franklin, Berlin, Germany

  • Dept. of Medicine I, Klinikum Munchen-Schwabing, Munchen, Germany

  • Abt. Hamatologie und Stammzelltransplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany

  • Department of Dermatology, University Hospital, University Duisburg-Essen, Essen, Germany

  • Medizinische Klinik m.S., Hamatologie, Onkologie und Tumorimmunologie, Charite, Universitatsmedizin Berlin, Berlin, Germany

  • Department of Medicine A / Hematology and Oncology, University of Muenster, Muenster, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany

  • University Hospital, Duesseldorf, Germany

  • Dept. of Medicine III, University Hospital, Mainz, Germany

  • Dept of Pediatrics, University Hospital Frankfurt, Frankfurt, Germany

  • Department of Hematology and Oncology, Klinikum Nuernberg, Nuernberg, Germany

  • Carl Gustav Carus TU-Dresden, Dresden, Germany,

  • Department of Hematology/Oncology and Stem Cell Transplantation, University Medical Center, Freiburg, Germany

  • Dept. Hematology, Hemostaseology, Oncology & Stem Cell Transplantation, Hannover Medical School, Hannover, Germany

  • Hematology & Oncology, Department of Medicine, University Hospital Tuebingen, Tuebingen, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

  • Infektiologikum, Frankfurt/Main, Germany

  • Department of Stem Cell Transplantation, University of Essen, Essen, Germany,

  • Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany

  • Department of Hematology and Oncology, Charite Campus Benjamin Franklin and Mitte, Berlin, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • AF4/FMR2 Family Member 1

  • B-lymphocyte antigen CD20

  • Histone-lysine N-methyltransferase 2A

  • White Blood Cell

Drug/Treatment

  • PEG-asparaginase

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Asparaginase

  • Prednisone

  • Rituximab

  • Imatinib

  • IkT001

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved